Financial Data and Key Metrics Changes - Total net sales for Q3 2021 were $58.4 million, up 24% compared to $47.1 million in Q3 2020, exceeding the previous outlook of $57 million to $58 million [25][26] - Gross profit for Q3 2021 was $45.3 million, or 77.6% of net sales, compared to 74.1% in Q3 2020 [28] - Net income in Q3 2021 was $6 million, or $0.12 per diluted share, compared to $3.9 million, or $0.08 per share in Q3 2020 [35][36] Business Line Data and Key Metrics Changes - ICL sales represented 93% of total company net sales for Q3 2021, with other products accounting for 7% [27] - Global ICL sales growth was up 31% year-over-year, with expectations for Q4 to exceed 40% growth [26][24] Market Data and Key Metrics Changes - ICL unit growth by geography included: Japan up 44%, South Korea up 21%, India up 338%, Germany up 25%, European distributor markets up 22%, Middle East and North Africa up 242%, and the U.S. up 66% compared to the prior year quarter [16] - China remains the largest market, with distributor inventory levels drawn down to historically low levels to meet demand [11] Company Strategy and Development Direction - The company is raising its full-year fiscal 2021 net sales outlook to a range of $230 million to $231 million, representing over 40% year-over-year growth [24] - Strategic imperatives include increasing marketing investments in key U.S. cities and expanding engagement with surgeons [19][21] - The company plans to open an ICL Experience Center in California in the first half of 2022 to enhance surgeon training and marketing education [23] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming temporary supply chain challenges and anticipates catching up on backlog in Q4 and Q1 2022 [50][54] - The company remains optimistic about achieving a compound annual growth rate of over 25% from 2020 to 2022, despite the impact of COVID-19 [24][68] Other Important Information - Cash and cash equivalents as of October 1, 2021, totaled $196.2 million, up from $152.5 million at the end of Q4 2020 [37] - The company plans to participate in several upcoming investor events, including the Canaccord Genuity Virtual MedTech & Diagnostics Forum [38] Q&A Session Summary Question: Regarding the backlog of 20,000 lenses - Management confirmed that the majority of the backlog is related to China and estimated that it could represent at least $65 million in revenue for the quarter if shipped [42] Question: Timing for distributor restocking - Management indicated that replenishment of inventory in China is already underway and they are prepared for the next big season starting in January [45] Question: Supply chain issues and their impact - Management clarified that the supply chain issues were not exclusive to China but were managed effectively to meet critical demand [88] Question: Expectations for U.S. market penetration post-launch - Management aims to achieve at least 20% market share in the U.S. within two to three years post-approval [95] Question: Growth driven by refractive market versus conversions - Management stated that the refractive market grows in the mid-single digits, while the company is growing at least 25% plus, indicating market share gains [82]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 1, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic ...

Financial Data and Key Metrics Changes - Total net sales for Q2 2021 were $62.4 million, up 77% compared to $35.2 million in Q2 2020, and up 23% sequentially from Q1 2021 [26][34] - Gross profit for Q2 2021 was $49.2 million, representing 78.9% of net sales, compared to 69.4% in Q2 2020 [28] - Operating income in Q2 2021 was $10.7 million, or 17.2% of net sales, compared to an operating loss of $600,000 in Q2 2020 [33] - Net income for Q2 2021 was $8.6 million, or $0.17 per diluted share, compared to a net loss of $1.2 million in Q2 2020 [34] Business Line Data and Key Metrics Changes - Global ICL unit growth for Q2 2021 was up 79% year-over-year, driving net sales growth [11] - ICL sales represented 95% of total company net sales for Q2 2021, with other products making up 5% [27] - The year-over-year increase in net sales for Q2 2021 was primarily due to global ICL sales growth, which was up 93% [26] Market Data and Key Metrics Changes - In China, ICL unit growth was up 65%, while Japan saw a 95% increase, and South Korea experienced a 57% rise [11] - The U.S. market reported a 255% increase in ICL sales year-over-year [11] - The Middle East and North Africa saw a staggering 378% growth in ICL sales [11] Company Strategy and Development Direction - The company is focusing on premium lens-based business and greater revenue per procedure, anticipating a shift from laser vision correction to ICL [18] - STAAR is increasing its net sales outlook for the full year fiscal 2021 to a range of $227 million to $230 million, up from a previous outlook of $215 million to $217 million [24] - The company is preparing for broader commercialization of the EVO lens and continues to work on regulatory pathways for marketing approval outside of Europe [19][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth opportunities, citing a third-party research firm naming STAAR the fastest-growing company in ophthalmology [22] - The company remains mindful of ongoing COVID-19 challenges but is optimistic about continued demand for EVO lenses [23] - Management highlighted the importance of in-person trade shows and conferences for advancing commercialization strategies [20] Other Important Information - Cash and cash equivalents as of July 2, 2021, totaled $173.1 million, up from $152.5 million at the end of Q4 2020 [36] - The company plans to participate in several investor conferences in the coming weeks [37] Q&A Session Summary Question: Comments on the dynamics between laser vision correction and ICL in China and Europe - Management noted that ICL is gaining ground among moderate myopia patients, with studies supporting higher patient satisfaction compared to laser vision correction [42] Question: Expectations for revenue building for the U.S. launch of EVO - Management indicated strong enthusiasm from surgeons for the EVO lens and expects significant market share growth similar to past experiences in China [51][53] Question: Plans for training U.S. surgeons for EVO - Management confirmed that training materials and certification requirements are ready, and they do not foresee training as a limiting factor [92] Question: Impact of COVID variants on business in China and Japan - Management reported limited disruptions in China due to COVID, while Japan experienced a slight decrease in lens implants during the Olympics, but expects a return to normal [64] Question: Future of current Visian ICL lenses post-EVO approval - Management stated that current Visian ICL lenses will continue to be sold alongside EVO due to the advantages of the new lens [68]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 2, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic Oc ...

Financial Data and Key Metrics Changes - Total net sales for Q1 2021 were $50.8 million, up 44% compared to $35.2 million in Q1 2020 and up 10% sequentially from Q4 2020 [14] - Gross profit for Q1 2021 was $39.1 million or 77.1% of net sales, compared to $24.8 million or 70.4% of net sales in Q1 2020 [16] - Net income in Q1 2021 was $5 million or $0.10 per diluted share, compared to a net loss of $134,000 in Q1 2020 [20] Business Line Data and Key Metrics Changes - ICL sales represented 93% of total company net sales for Q1 2021, with strong growth across various regions [14] - Global ICL unit growth for Q1 2021 was up 54% year-over-year, with significant increases in China (up 63%), Japan (up 72%), and the US (up 46%) [6][14] Market Data and Key Metrics Changes - The company anticipates Q2 2021 net sales to be approximately 50% year-over-year revenue growth compared to Q2 2020 [14] - The US market is expected to see a significant introduction of EVO lenses pending FDA approval, with a planned launch in Q4 2021 [12][21] Company Strategy and Development Direction - The company is focusing on expanding its EVO Visian ICL family of lenses and enhancing direct-to-consumer outreach to build awareness [8][10] - A new advertising campaign featuring a Japanese celebrity aims to increase visibility and patient engagement in Japan [9] Management's Comments on Operating Environment and Future Outlook - Management views the current growth as a continuation of pre-COVID momentum, with expectations for sustained growth in the coming quarters [24][25] - The company anticipates total net sales for fiscal 2021 to be approximately $215 million to $217 million, representing over 30% year-over-year growth [13] Other Important Information - The company plans to participate in several upcoming conferences, including the Oppenheimer Medtech Tools and Diagnostic Summit [21] - The company expects to maintain gross margins in the mid-70% range for Q2 and the fiscal year 2021 [16] Q&A Session Summary Question: Source of growth and awareness - Management does not see the growth as a catch-up but as a continuation of momentum pre-COVID, with strong patient referrals and social media engagement driving awareness [24] Question: US and EU implant numbers - Management noted a significant uptake in Europe and the US, attributing it to prior efforts in building awareness and patient satisfaction [25]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: April 2, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic O ...

Financial Data and Key Metrics Changes - Total net sales for Q4 2020 were $46 million, an increase of 18% compared to $38.9 million in Q4 2019, but down 2% sequentially from Q3 2020 [29] - Gross profit for Q4 2020 was $34.3 million, or 74.6% of net sales, compared to $28.8 million, or 74.1% of net sales in Q4 2019 [31] - Operating income in Q4 2020 was $4.1 million, or 8.8% of sales, compared to $2.3 million, or 6% of sales for Q4 2019 [39] - Net income for Q4 2020 was $3.3 million, or $0.07 per diluted share, compared to $6.4 million, or $0.14 per share in Q4 2019 [40] - Adjusted net income for Q4 2020 was $6.8 million, or $0.14 per diluted share, compared to $5.5 million, or $0.12 per diluted share in Q4 2019 [41] Business Line Data and Key Metrics Changes - ICL sales represented 87% of total company net sales for Q4 2020, consistent with recent trends [31] - ICL unit growth in Q4 2020 showed strong recovery, with significant growth in markets such as China (up 17%), Japan (up 52%), and Germany (up 28%) compared to the prior year quarter [13] Market Data and Key Metrics Changes - The total refractive industry procedures declined by an estimated 21% in 2020 compared to the prior year, while STAAR's ICL units were up 11% [15] - The Middle East remained the most challenged market due to COVID-19 during Q4 2020 [14] Company Strategy and Development Direction - The strategic imperative is to position the EVO ICL family of lenses as a transformational pathway for visual freedom, aiming to capture a disproportionate share of the projected 5.8 million annual refractive procedures by 2025 [17] - The company is focused on increasing consumer awareness, surgeon commitment, and introducing innovative products to new markets [19][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum of the business, with expectations for healthy year-over-year growth in the first half of 2021 [51] - The company plans to increase capital expenditures in 2021 to support manufacturing capacity and infrastructure scalability, with anticipated spending between $15 million to $20 million [43][44] Other Important Information - The company welcomed two new members to the Board of Directors, Dr. Elizabeth Yeu and Dr. Peony Yu [29] Q&A Session Summary Question: Long-term targets for ICL growth - Management is confident in achieving a three-year growth rate of 25% and 35% ICL unit growth by the end of 2022, with strong momentum continuing into 2021 [51] Question: Infrastructure investments for EVO and VIVA - Management indicated that investments in infrastructure are necessary for scaling operations, with expectations for operating expense leverage in the future [60] Question: Update on VIVA and U.S. EVO launch - The rollout of VIVA in Europe is planned with additional surgeon training and a playbook ready by September, while the U.S. EVO launch is expected to have strong consumer outreach and partnerships [72] Question: Distributor trends and inventory management - Management noted that distributor stocking and destocking patterns are normal, with no unusual trends observed [75] Question: Demographics for EVO in the U.S. - The target demographic for EVO in the U.S. is similar to that in Asia, focusing on young professionals seeking visual freedom [82] Question: Cash flow and potential M&A - Management emphasized that the shelf registration is standard corporate governance, and the company is focused on organic growth with a healthy balance sheet [88][90] Question: Product mix and pricing strategy - The shift towards lower diopter lenses is supported by clinical validation and pricing strategies to encourage surgeons and patients to choose ICL over LASIK [96] Question: Market dynamics in China post-New Year - Management expressed optimism about strong growth in China following the New Year, with expectations for robust distribution in Q2 and Q3 [99]

Financial Data and Key Metrics Changes - Total net sales for Q3 2020 were $47.1 million, up 21% compared to $39.1 million in Q3 2019, and up 34% sequentially from Q2 2020 [22] - Gross profit for Q3 2020 was $34.9 million, representing 74.1% of net sales, compared to 74.4% in the prior year quarter [23] - Operating income in Q3 2020 was $4.9 million, or 10.4% of net sales, compared to $3.3 million, or 8.5% of net sales in the year-ago quarter [28] - Net income for Q3 was $4 million, or $0.08 per diluted share, compared to $2.4 million, or $0.05 per share in the prior year [28] - Cash and cash equivalents as of October 2, 2020, totaled $128.3 million, up $12 million from $116.3 million at the end of Q2 2020 [29] Business Line Data and Key Metrics Changes - ICL sales represented 88% of total company net sales for Q3 2020, consistent with recent trends [23] - Research and development expenses increased to $8.8 million in Q3 2020 from $6.2 million in the year-ago quarter, primarily due to increased clinical expenses [27] Market Data and Key Metrics Changes - ICL unit growth in Q3 was 25% globally, with standout markets including China (up 33%), Japan (up 67%), and South Korea (up 21%) [10][11] - Excluding India and the Middle East, global ICL unit growth would have been 32% [11] Company Strategy and Development Direction - The company aims to increase global market share from 10% to 20%-30% in the foreseeable future [21] - The launch of the EVO Viva presbyopia correcting lens in Europe is part of the company's strategy to expand its product offerings [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for EVO lenses, reflecting pre-COVID levels, and reiterated the outlook for Q4 2020 with expected net sales of approximately $43 million [21] - The company is monitoring COVID-19 developments and their potential impact on business operations [12] Other Important Information - The company has made progress on two new products for the U.S. and European markets, with plans for FDA submission in the first half of 2021 [17] - The EVO website saw a 250% increase in unique visitors year-to-date through Q3 2020 [16] Q&A Session Summary Question: Pricing and Demand in China - Management confirmed that pricing in China improved, with a strong quarter for average selling prices globally [34] - The majority of demand observed is new demand rather than deferred procedures [37] Question: Refractive Restart Program - The program has helped surgeons attract patients by offering one lens free of charge for bilateral implant patients, resulting in a 70% sequential increase in units [46] Question: Market Share in Japan - Japan has seen significant growth, with the company achieving over 30% market share, and plans to continue working with key opinion leaders [53] Question: Fourth Quarter Expectations - Management expects double-digit growth in Q4, but will be cautious due to potential COVID-19 impacts [71]

| --- | --- | --- | --- | --- | |--------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | STAAR S URGICAL | | | | | | C OMPANY | | | | | | | | | | | | I NVESTOR PRESENTATION S EPTEMBER 2020 | | | | | ⊙STAARSURGICAL OSTAARSURGICAL™ | --- | --- | |---------|------------| | | | | | | | | | | Forward | | | Looking | Statements | Evolution in Visual Freedom™ All statements in this presentation that are not statements of historical fact are forward-lookin ...

Financial Data and Key Metrics Changes - Total net sales for Q2 2020 were $35.2 million, consistent with Q1 2020 but down from $39.7 million in Q2 2019, attributed to COVID-related market closures [22] - Gross profit for Q2 2020 was $24.4 million, or 69.4% of net sales, down from 70.4% in Q1 2020 and 75.4% in Q2 2019, primarily due to manufacturing pause costs and geographic sales mix [23] - Net loss for Q2 2020 was $1.2 million, or $0.03 per share, compared to a net income of $3.9 million, or $0.08 per share, in Q2 2019 [29] Business Line Data and Key Metrics Changes - ICL sales represented 87% of total company net sales for Q2 2020, consistent with Q2 2019 results [22] - Research and development expense was $7.3 million in Q2 2020, up from $6.1 million in Q2 2019, due to increased clinical expenses associated with EVO clinical trials [27] Market Data and Key Metrics Changes - In June, year-over-year ICLM plan procedures recorded strong growth: 65% in Japan, 24% in the rest of Asia Pacific, 17% in Germany, 15% in distributor markets in Europe, and 11% in Korea [12] - China experienced a 6% increase in units in Q2 2020, with a strong demand for refractive procedures as the peak season began [48] Company Strategy and Development Direction - The company aims to achieve a 20% share of the refractive procedure market in China by year-end, supported by a digital marketing strategy targeting 100 million visitors [14] - Plans to restart manufacturing in Nidau, Switzerland, in 2021, and to prepare the Lake Forest, California facility for EVO Viva lens production [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a sequential revenue increase of at least 20% in Q3 2020, driven by recovery in various markets, particularly in Asia [21] - The impact of COVID-19 on sales appears to be lessening, with customers indicating no desire to pause procedures again unless mandated [20] Other Important Information - The company has received CE mark approval for its EVO Viva presbyopia lens, targeting a market of 1.7 billion people globally [17] - Cash and cash equivalents as of July 3, 2020, totaled $116.3 million, up from $110.9 million at the end of Q1 2020 [31] Q&A Session Summary Question: Confidence in expected sequential growth in Q3 - Management's confidence is based on recovery in multiple markets, particularly in Asia, with strong July results and peak season in China [36] Question: Margin structure for EVO Viva - Initial production of EVO Viva will be out of Monrovia, with expected gross margins in line with current EVO lenses [38] Question: Trends in China and market share - The company is seeing share gains from moderate myopes and is currently around 18% market share in China, aiming for 20% by year-end [40] Question: U.S. rollout progression for EVO - The U.S. market is more fragmented, but a "refractive restart" program is expected to facilitate a quick ramp-up in adoption [42] Question: Impact of COVID-19 on China’s busy season - There has been no disruption in business in China, with high demand for refractive procedures and effective consumer outreach strategies [68] Question: Initial interest in EVO in Europe - The EVO family of lenses is expected to expand the target demographic for surgeons, increasing overall volume and specificity in marketing [70]